Biomerieux Sa Stock EBITDA

BIM Stock  EUR 98.70  2.20  2.28%   
Biomerieux SA fundamentals help investors to digest information that contributes to Biomerieux's financial success or failures. It also enables traders to predict the movement of Biomerieux Stock. The fundamental analysis module provides a way to measure Biomerieux's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biomerieux stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Biomerieux SA Company EBITDA Analysis

Biomerieux's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Biomerieux EBITDA

    
  1.01 B  
Most of Biomerieux's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biomerieux SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, Biomerieux SA reported earnings before interest,tax, depreciation and amortization of 1.01 B. This is 15.66% higher than that of the Healthcare sector and 192.53% higher than that of the Diagnostics & Research industry. The ebitda for all France stocks is 73.97% higher than that of the company.

Biomerieux EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biomerieux's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biomerieux could also be used in its relative valuation, which is a method of valuing Biomerieux by comparing valuation metrics of similar companies.
Biomerieux is currently under evaluation in ebitda category among its peers.

Biomerieux Fundamentals

About Biomerieux Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Biomerieux SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biomerieux using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biomerieux SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Biomerieux Stock

Biomerieux financial ratios help investors to determine whether Biomerieux Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biomerieux with respect to the benefits of owning Biomerieux security.